SIGA Technologies (NASDAQ:SIGA) announced Thursday that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approved ...

Infection with mpox causes a fever and swollen lymph nodes, followed by a distinctive rash that develops into pus-filled blisters. Currently, two companies of Japan and Denmark produce the vaccine ...

On Thursday, the Japan Ministry of Health, Labour and Welfare approved SIGA Technologies (NASDAQ:SIGA) antiviral treatment ...

More than 44% of the 10,533 confirmed mpox cases in Congo are children under 15 years old, the latest Africa CDC data shows. The vaccine from Japan will be used on children aged zero to five ...

Our reporter went to Congo, where the mpox epidemic has reached the teeming capital, infecting children and their mothers, ...

French health officials announced on Tuesday its first case of a dangerous new strain of the mpox virus that has created ...

Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan ...

Siga Technologies (SIGA)’ antiviral treatment Tepoxx, has received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, as ...

Mpox vaccines that young children can use will arrive from Japan next week, a crucial step in reducing the spread of the disease that has killed about 1,200 people in the Democratic Republic of ...

A formal ceremony heralded the start of the Japan's sumo wrestling season at the Meiji Jingu shrine on Tuesday, two months ...

DAKAR, Dec 12 (Reuters) - Democratic Republic of Congo should start to receive three million doses of mpox vaccine from Japan next week that can be used on children, the Africa Centres for Disease ...

The Democratic Republic of Congo should start to receive 3 million doses of mpox vaccine from Japan next week that can be used for children, the Africa Centers for Disease Control and Prevention ...